Slingshot members are tracking this event:
Immunomedics releases Phase 2 study results on IMMU-132, as data show SACITUZUMAB GOVITECAN produces strong response in triple-negative breast cancer patients
Slingshot Insights Explained
Mar 15, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Sacituzumab Govitecan, Triple Negative Breast Cancer, Phase 2, Immu-132